dimethyl-4-(2-fluorophenyl)-2-oxo-butylphosphonate | 221631-40-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: dimethyl-4-(2-fluorophenyl)-2-oxo-butylphosphonate
• 英文别名: 1-Dimethoxyphosphoryl-4-(2-fluorophenyl)butan-2-one
• CAS: 221631-40-9
• 化学式: C₁₂H₁₆FO₄P
• 分子量: 274.229
• InChiKey: KOYCWIBTABZOTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  dimethyl-4-(2-fluorophenyl)-2-oxo-butylphosphonate 在 palladium on activated charcoal 甲醇 、 lithium aluminium tetrahydride 、 (-)-(S)-BINAL-H 、 氢气 、 sodium hexamethyldisilazane 、 二异丁基氢化铝 、 potassium carbonate 、 对甲苯磺酸 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 7-{(1R,2R,3R,5S)-2-[(R)-5-(2-Fluoro-phenyl)-3-hydroxy-pentyl]-3,5-dihydroxy-cyclopentyl}-heptanoic acid
  参考文献：
  名称：

  Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues

  摘要：

  The in vitro evaluation of a series of saturated prostaglandins revealed that compounds with omega chain aromatic rings retain nanomolar potency for the human prostaglandin F receptor (hFP receptor), exemplified by compound 8. In contrast, the double bonds are required for activity in the series with an acyclic omega chain as in PGF(2 alpha). (C) 2000 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(00)00273-0
• 作为产物：
  描述：

  3-(2-氟苯基)丙酸 在 甲醇 、 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 生成 dimethyl-4-(2-fluorophenyl)-2-oxo-butylphosphonate
  参考文献：
  名称：

  Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues

  摘要：

  The in vitro evaluation of a series of saturated prostaglandins revealed that compounds with omega chain aromatic rings retain nanomolar potency for the human prostaglandin F receptor (hFP receptor), exemplified by compound 8. In contrast, the double bonds are required for activity in the series with an acyclic omega chain as in PGF(2 alpha). (C) 2000 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(00)00273-0

文献信息

• C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
  申请人：The Procter & Gamble Co.

  公开号：US06410780B1

  公开（公告）日：2002-06-25

  The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R1, R2, R3, R4, R5, R6, W, X, Z, a, b, p and q are defined below. This invention also includes optical isomers, diastereomers and enantiomers of formula (I), and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using these compounds or the compositions containing them.

  该发明提供了新型前列腺素类似物。具体来说，本发明涉及具有以下式(I)结构的化合物，其中R1、R2、R3、R4、R5、R6、W、X、Z、a、b、p和q如下所定义。本发明还包括式(I)的光学异构体、二对映异构体和对映异构体，以及其药用可接受盐、生物水解酰胺、酯和亚酰胺。本发明的化合物可用于治疗各种疾病和症状，如骨疾病和青光眼。因此，该发明进一步提供包含这些化合物的药物组合物。该发明还提供了使用这些化合物或含有它们的组合物治疗骨疾病和青光眼的方法。
• Aromatic C.sub.16 -C.sub.20 -substituted tetrahydro prostaglandins
  申请人：The Procter & Gamble Company

  公开号：US06107338A1

  公开（公告）日：2000-08-22

  The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, X, Y, and Z are defined below. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using theses compounds or the compositions containing them.

  本发明提供了新型PGF类似物。特别地，本发明涉及具有以下结构式的化合物：##STR1## 其中R.sub.1，R.sub.2，R.sub.3，R.sub.4，X，Y和Z的定义如下。本发明还包括上述公式的光学异构体、对映异构体和对映体，以及其药学上可接受的盐、生物可水解酰胺、酯和亚胺。本发明的化合物对于治疗各种疾病和病症，如骨疾和青光眼，有用。因此，本发明还提供包含这些化合物的药物组合物。本发明还提供使用这些化合物或含有它们的组合物治疗骨疾和青光眼的方法。
• C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists
  申请人：The Procter & Gamble Co.

  公开号：US06444840B1

  公开（公告）日：2002-09-03

  The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R1, R2, R3, R4, R5, R6, W, X, Z, a, b, p and q are defined below. This invention also includes optical isomers, diastereomers and enantiomers of formula (I), and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using these compounds or the compositions containing them.

  该发明提供了新颖的前列腺素类似物。具体而言，本发明涉及具有以下结构的化合物（I）的结构，其中R1、R2、R3、R4、R5、R6、W、X、Z、a、b、p和q如下所定义。本发明还包括化合物（I）的光学异构体、顺反异构体和对映体，以及其药用可接受的盐、生物水解酰胺、酯和亚酰胺。本发明的化合物对于治疗各种疾病和症状，如骨骼疾病和青光眼等，具有用途。因此，该发明进一步提供了包含这些化合物的药物组合物。该发明还进一步提供了使用这些化合物或含有它们的组合物治疗骨骼疾病和青光眼的方法。
• AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS
  申请人：Duke University

  公开号：EP1021402B1

  公开（公告）日：2005-11-23
• C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS FP AGONISTS
  申请人：Duke University

  公开号：EP1066254B1

  公开（公告）日：2005-05-25